The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas

Kristina M. Bacon, Peter J. Hotez, Stephanie D. Kruchten, Shaden Kamhawi, Maria Elena Bottazzi, Jesus G. Valenzuela, Bruce Lee

Research output: Contribution to journalArticle

Abstract

Cutaneous leishmaniasis (CL) and its associated complications, including mucocutaneous leishmaniasis (MCL) and diffuse CL (DCL) have emerged as important neglected tropical diseases in Latin America, especially in areas associated with human migration, conflict, and recent deforestation. Because of the limitations of current chemotherapeutic approaches to CL, MCL, and DCL, several prototype vaccines are in different states of product and clinical development. We constructed and utilized a Markov decision analytic computer model to evaluate the potential economic value of a preventative CL vaccine in seven countries in Latin America: Bolivia, Brazil, Colombia, Ecuador, Mexico, Peru, and Venezuela. The results indicated that even a vaccine with a relatively short duration of protection and modest efficacy could be recommended for use in targeted locations, as it could prevent a substantial number of cases at low-cost and potentially even result in cost savings. If the population in the seven countries were vaccinated using a vaccine that provides at least 10 years of protection, an estimated 41,000-144,784 CL cases could be averted, each at a cost less than the cost of current recommended treatments. Further, even a vaccine providing as little as five years duration of protection with as little as 50% efficacy remains cost-effective compared with chemotherapy; additional scenarios resembling epidemic settings such as the one that occurred in Chaparral, Colombia in 2004 demonstrate important economic benefits.

Original languageEnglish (US)
Pages (from-to)480-486
Number of pages7
JournalVaccine
Volume31
Issue number3
DOIs
StatePublished - Jan 7 2013
Externally publishedYes

Fingerprint

Leishmaniasis Vaccines
cutaneous leishmaniasis
Cutaneous Leishmaniasis
economic valuation
Mucocutaneous Leishmaniasis
Vaccines
Economics
vaccines
Costs and Cost Analysis
Colombia
Latin America
leishmaniasis
Diffuse Cutaneous Leishmaniasis
Human Migration
Neglected Diseases
Bolivia
Ecuador
Venezuela
Peru
Cost Savings

Keywords

  • Cutaneous leishmaniasis
  • Economics
  • Latin America
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Bacon, K. M., Hotez, P. J., Kruchten, S. D., Kamhawi, S., Bottazzi, M. E., Valenzuela, J. G., & Lee, B. (2013). The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. Vaccine, 31(3), 480-486. https://doi.org/10.1016/j.vaccine.2012.11.032

The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. / Bacon, Kristina M.; Hotez, Peter J.; Kruchten, Stephanie D.; Kamhawi, Shaden; Bottazzi, Maria Elena; Valenzuela, Jesus G.; Lee, Bruce.

In: Vaccine, Vol. 31, No. 3, 07.01.2013, p. 480-486.

Research output: Contribution to journalArticle

Bacon, KM, Hotez, PJ, Kruchten, SD, Kamhawi, S, Bottazzi, ME, Valenzuela, JG & Lee, B 2013, 'The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas', Vaccine, vol. 31, no. 3, pp. 480-486. https://doi.org/10.1016/j.vaccine.2012.11.032
Bacon KM, Hotez PJ, Kruchten SD, Kamhawi S, Bottazzi ME, Valenzuela JG et al. The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. Vaccine. 2013 Jan 7;31(3):480-486. https://doi.org/10.1016/j.vaccine.2012.11.032
Bacon, Kristina M. ; Hotez, Peter J. ; Kruchten, Stephanie D. ; Kamhawi, Shaden ; Bottazzi, Maria Elena ; Valenzuela, Jesus G. ; Lee, Bruce. / The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. In: Vaccine. 2013 ; Vol. 31, No. 3. pp. 480-486.
@article{da15b21da88b4c24b883429bd77957e5,
title = "The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas",
abstract = "Cutaneous leishmaniasis (CL) and its associated complications, including mucocutaneous leishmaniasis (MCL) and diffuse CL (DCL) have emerged as important neglected tropical diseases in Latin America, especially in areas associated with human migration, conflict, and recent deforestation. Because of the limitations of current chemotherapeutic approaches to CL, MCL, and DCL, several prototype vaccines are in different states of product and clinical development. We constructed and utilized a Markov decision analytic computer model to evaluate the potential economic value of a preventative CL vaccine in seven countries in Latin America: Bolivia, Brazil, Colombia, Ecuador, Mexico, Peru, and Venezuela. The results indicated that even a vaccine with a relatively short duration of protection and modest efficacy could be recommended for use in targeted locations, as it could prevent a substantial number of cases at low-cost and potentially even result in cost savings. If the population in the seven countries were vaccinated using a vaccine that provides at least 10 years of protection, an estimated 41,000-144,784 CL cases could be averted, each at a cost less than the cost of current recommended treatments. Further, even a vaccine providing as little as five years duration of protection with as little as 50{\%} efficacy remains cost-effective compared with chemotherapy; additional scenarios resembling epidemic settings such as the one that occurred in Chaparral, Colombia in 2004 demonstrate important economic benefits.",
keywords = "Cutaneous leishmaniasis, Economics, Latin America, Vaccine",
author = "Bacon, {Kristina M.} and Hotez, {Peter J.} and Kruchten, {Stephanie D.} and Shaden Kamhawi and Bottazzi, {Maria Elena} and Valenzuela, {Jesus G.} and Bruce Lee",
year = "2013",
month = "1",
day = "7",
doi = "10.1016/j.vaccine.2012.11.032",
language = "English (US)",
volume = "31",
pages = "480--486",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas

AU - Bacon, Kristina M.

AU - Hotez, Peter J.

AU - Kruchten, Stephanie D.

AU - Kamhawi, Shaden

AU - Bottazzi, Maria Elena

AU - Valenzuela, Jesus G.

AU - Lee, Bruce

PY - 2013/1/7

Y1 - 2013/1/7

N2 - Cutaneous leishmaniasis (CL) and its associated complications, including mucocutaneous leishmaniasis (MCL) and diffuse CL (DCL) have emerged as important neglected tropical diseases in Latin America, especially in areas associated with human migration, conflict, and recent deforestation. Because of the limitations of current chemotherapeutic approaches to CL, MCL, and DCL, several prototype vaccines are in different states of product and clinical development. We constructed and utilized a Markov decision analytic computer model to evaluate the potential economic value of a preventative CL vaccine in seven countries in Latin America: Bolivia, Brazil, Colombia, Ecuador, Mexico, Peru, and Venezuela. The results indicated that even a vaccine with a relatively short duration of protection and modest efficacy could be recommended for use in targeted locations, as it could prevent a substantial number of cases at low-cost and potentially even result in cost savings. If the population in the seven countries were vaccinated using a vaccine that provides at least 10 years of protection, an estimated 41,000-144,784 CL cases could be averted, each at a cost less than the cost of current recommended treatments. Further, even a vaccine providing as little as five years duration of protection with as little as 50% efficacy remains cost-effective compared with chemotherapy; additional scenarios resembling epidemic settings such as the one that occurred in Chaparral, Colombia in 2004 demonstrate important economic benefits.

AB - Cutaneous leishmaniasis (CL) and its associated complications, including mucocutaneous leishmaniasis (MCL) and diffuse CL (DCL) have emerged as important neglected tropical diseases in Latin America, especially in areas associated with human migration, conflict, and recent deforestation. Because of the limitations of current chemotherapeutic approaches to CL, MCL, and DCL, several prototype vaccines are in different states of product and clinical development. We constructed and utilized a Markov decision analytic computer model to evaluate the potential economic value of a preventative CL vaccine in seven countries in Latin America: Bolivia, Brazil, Colombia, Ecuador, Mexico, Peru, and Venezuela. The results indicated that even a vaccine with a relatively short duration of protection and modest efficacy could be recommended for use in targeted locations, as it could prevent a substantial number of cases at low-cost and potentially even result in cost savings. If the population in the seven countries were vaccinated using a vaccine that provides at least 10 years of protection, an estimated 41,000-144,784 CL cases could be averted, each at a cost less than the cost of current recommended treatments. Further, even a vaccine providing as little as five years duration of protection with as little as 50% efficacy remains cost-effective compared with chemotherapy; additional scenarios resembling epidemic settings such as the one that occurred in Chaparral, Colombia in 2004 demonstrate important economic benefits.

KW - Cutaneous leishmaniasis

KW - Economics

KW - Latin America

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84871670712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871670712&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.11.032

DO - 10.1016/j.vaccine.2012.11.032

M3 - Article

VL - 31

SP - 480

EP - 486

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 3

ER -